TRPV1 and COVID-19: While the direct interaction of SARS-CoV-2 with TRPV1/A1 receptors awaits investigation, increased levels of endogenous mediators during COVID-19, particularly elevated PGE2 in severe cases (44, 45) and dysregulated BK signaling (46) in patients with COVID-19 pneumonia (47), suggest potential involvement.